medRxiv preprint doi: https://doi.org/10.1101/2024.03.20.24304569; this version posted March 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

European Health Regulations Reduce Registry-Based Research

- Oscar Brück¹, Enni Sanmark², Ville Ponkilainen³, Alexander Bützow⁴, Aleksi Reito³,
 Joonas H. Kauppila^{5,6}, Ilari Kuitunen⁷
- 7 8

1

2 3 4

- 9 1 Hematoscope Lab, Comprehensive Cancer Center & Center of Diagnostics,
- 10 Helsinki University Hospital, Helsinki, Finland & Department of Oncology, University 11 of Helsinki, Helsinki, Finland
- 12 2 Department of Otorhinolaryngology and Phoniatrics Head and Neck Surgery,
- Helsinki University Hospital, Finland and Faculty of Medicine, University of Helsinki,
 Finland.
- 15 3 Center for Musculoskeletal Diseases, Tampere University Hospital, Tampere,
 16 Finland
- 17 4 Krogerus Attorneys Ltd, Helsinki, Finland
- 18 5 Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland
- 19 6 Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska
- 20 University Hospital, Stockholm, Sweden
- 21 7 Department of Pediatrics, Institute of Clinical Medicine, University of Eastern Finland
- 22 and Kuopio University Hospital, Kuopio, Finland
- 23
- 24
- 25
- 26

27 ADDRESS FOR CORRESPONDENCE

- 28 Dr. O. Brück, Hematoscope Lab, Biomedicum I, Haartmaninkatu 8, P.O. Box 700,
- 29HelsinkiFIN-00290,Finland.E-mail:oscar.bruck@hus.fiORCID30https://orcid.org/0000-0002-7842-9419.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 ABSTRACT

32 The European Health Data Space regulation (EHDS) has been proposed to harmonize health data processing. Given its parallels with the Act on Secondary Use of Health 33 34 and Social Data (Secondary Use Act) implemented in Finland in 2020, this study 35 examines the consequences of heightened privacy constraints on registry-based 36 medical research. Between 2020 and 2023, a median of 5.5% fewer data permits were 37 approved annually by Finnish university hospitals. Based on linear regression 38 modelling, we estimated a reduction of 46.9% in new data permits nationally in 2023 39 compared to the expected count. Similar changes were not observed in other medical 40 research types highlighting the consequences of excessive data privacy laws on 41 registry-based medical research.

42 INTRODUCTION

43 Registry-based medical research forms an integral pillar of modern healthcare. 44 Medical registries are invaluable resources to generate evidence-based medical 45 guidelines and develop innovations such as effective diagnostic and monitoring tools. 46 However, this progress has been subjected to growing regulatory burden in the 47 European Union (EU), particularly in the realm of data privacy and security. The 48 General Data Protection Regulation (GDPR), implemented in 2018, has strengthened 49 personal data protection rights by providing individuals with greater control over their 50 data, and imposing stricter obligations on data controllers and processors. Currently, 51 the European Health Data Space regulation (EHDS) is under preparation to establish 52 a common framework for the governance and sharing of health data across the 53 European Union. While this initiative holds promise for facilitating cross-border access 54 to health data, it also introduces additional layers of bureaucracy and potential delays 55 in research and innovation raising questions of its effectiveness¹.

To complement the GDPR, the Ministry of Social Affairs and Health introduced the Act 56 57 on the Secondary Use of Health and Social Data (Secondary Use Act) in Finland in 58 2019 and implemented it into use in April 2020. Its primary purpose was to facilitate 59 the effective and safe processing of personal social and health data for secondary 60 uses, such as research, policymaking, and healthcare management, in contrast to 61 primary uses, such as provision of healthcare services. Individual public health care 62 entities, such as university hospitals, retained the right to grant data permits to their 63 own data in single-registry studies. Instead, Findata was established as the centralized 64 data permit authority, *i.e.* a one-stop-agency granting data permits for secondary use, 65 combining data from private healthcare providers, the national Patient Data 66 Repository, or a combination of multiple social and health registries, with multiple other tasks, such as defining policies for safe data processing. 67

68 Despite these positive objectives, two independent surveys conducted in 2021 69 highlighted the discontent of the research community. The first study was directed to 70 medical doctors and revealed that out of 430 responders 79% experienced the data 71 permit process to have become more complex than before, 55% that research projects were delayed, and 64% that research costs had increased². Due to these issues, 42% 72 73 of responders reported that they had not initiated a study². Similar results were 74 reported in a second survey commissioned by the Ministry of Social Affairs and Health 75 where responders (n=260) evaluated that the Secondary Use Act had neither simplified the application process nor the combination of multiple registries³. 76

77 While the EHDS regulation is expected to harmonize the principles of health data 78 processing in the EU, there is little retrospective evidence on the impact of increasing 79 privacy regulations on registry-based social and medical research. Given its 80 considerable overlap with the Secondary Use Act, we sought to evaluate the impact of the regulation on registry-based research by examining data permit counts before 81 82 and after the implementation of the Act.

83

84 **METHODS**

85 Data permits

86 There are five university hospitals in Finland, located in Helsinki, Tampere, Kuopio, 87 Turku, and Oulu. When referencing these cities, we are specifically alluding to the 88 respective university hospitals. University hospitals serve as regional hubs for 89 specialized care and providing comprehensive medical services to their respective 90 catchment areas. The hospitals are well-equipped for registry-based research due to 91 their advanced IT infrastructure and larger patient populations, enabling them to 92 effectively collect, manage, and analyze large-scale health data both for primary and 93 secondary purposes.

94

95 After entry into force of the Secondary Use Act, both a study permit and data permit 96 were required to conduct registry-based research projects in Finland. In this study, we 97 employ the term 'data permit' as university hospitals can grant both study and data 98 permits but Findata can grant only data permits.

99

100 In January 2024, we solicited counts of new data permits for registry-based research, 101 specifically involving university hospital registries, from the research departments of 102 all five university hospitals (Helsinki, Turku, Tampere, Oulu, and Kuopio). To account 103 for variations in research funding and regulatory changes, we also requested data on 104 study permits for medical research involving subjects, human tissue, or medical 105 devices. Due to varying archiving practices, data from 2016-2023 were available from 106 Tampere, Oulu, Kuopio, and Helsinki, As data was accessible only from 2020-2023. 107 Turku was excluded in analyses requiring data prior to 2020.

108

109 We also solicited counts of new data permit (n=375) involving clinical data from 110 university hospitals and granted by Findata in 2020-2023. Recognizing that Findataapproved permits cover data from 1-5 hospitals, we integrated details on the annual 111 112 mean count of university hospitals covered by these permits (mean 2.2-2.6 in 2021-113 2023).

114

115 Statistical analysis

116 We fitted univariate linear regression analyses using data permit counts as covariate 117 and year as predictor and examined the slopes of the curves by extracting the 118 coefficient. We used the Mann-Kendall test to estimate trend over time. Based on prior 119 findings, we reasoned to test only whether the registry-based study count had 120 decreased since its implementation with the one-sided Mann-Kendall test^{2,3}. 121 Elsewhere, we applied the two-sided tests. We performed statistical analyses and 122 visualizations with R 4.0 using the packages base, sf, mapsFinland, ggplot2.

123

124 RESULTS

In 2020-2023, 1768 registry-based research data permits have been granted by 125 126 university hospitals (Fig. 1a). Most of these (n=595) were approved by Helsinki, 127 followed by Tampere (n=367), Turku (n=355), Oulu (n=231), and Kuopio (n=220). 128 Following a stable period between 2016 and 2019 (median 517, range 497-573; Fig. 129 1b), new data permit counts decreased rapidly across hospitals (tau -1, p=0.042, one-

130 sided Mann-Kendall test). Compared to 2019, there was a median decrease of 22.4 131 (range 9.7-31.7) data permits per year, representing an annual median reduction of 5.5% (range 3.4-10.5%). During the same time, 375 registry-based data permits were 132 133 approved by Findata (Fig. 1b). For unclear reasons, the rate of Findata-approved data 134 permits also decreased from 141 to 99 (29.8%) in 2023 (Fig. 1b).

135 Next, we examined data permit counts approved by university hospitals before and 136 after (2016-2017 vs. 2018-2019) the implementation of the GDPR. An annual median of 152 new registry research permits were approved pre-GDPR (Fig. 1b). While the 137 138 corresponding median in the following two years was 131, the count sharply increased 139 from 121 in 2018 to 138 permits in 2019 implying the GDPR had no conclusive impact 140 on data permit counts (Fig. 1b).

141 To estimate the decline in data permits, we examined the era before the implementation of the Secondary Use Act. From 2015 to 2019, a median of 1.9 (range 142 143 1.0-7.3) additional data permits were approved corresponding to a 0.70% (range 0.20-1.3%) yearly accumulation. Assuming that similar progress would have continued until 144 2023, we fitted a linear regression curve for each hospital and predicted that a total of 145 146 586.8 new data permits would have been granted in 2023 (Fig. 1c). The figure 147 contrasts with the 234 new data permits actually approved. Given that a portion of 148 multi-center permits have been directed to Findata and as Turku was excluded from 149 the analyses due to missing data, we included data permits accorded by Findata in 2023 (n=99) multiplied by 78.3% reflecting the percentage of data permits approved 150 151 by other university hospitals than Turku in 2023. The estimated reduction amounted 152 to $275.3 = 586.8 - 234.0 - (99.0 \times 0.78)$ data permits corresponding to a relative reduction of 314.2/586.8 = 46.9%. 153

154 To exclude other confounding factors, we examined the data permit counts for other 155 types of medical research (Fig. 1d). While the proportion of approved permits decreased in 2016-2023 (tau -0.54, p=0.061, two-sided Mann-Kendall test), the 156 157 changes did not coincide with neither the enactment of the GDPR nor of the Secondary 158 Use Act.

159

160 DISCUSSION

161 This retrospective observational cohort study demonstrates the devastating impact of the Secondary Use Act on registry-based studies only three years after its 162 implementation. The findings sharply contrast with the general positive attitude 163 164 towards secondary use of personal data in medical research⁴.

165 This study has several implications for efforts to understand the potential impact of the EHDS regulation on research and innovations. First, while registry-based research 166 could be previously performed with a minimal budget, solid funding has become a 167 168 necessity following the enactment of the Secondary Use Act. Primarily data 169 collections, but also application fees for submitting a study plan, adding researchers

170 to a valid permit, and processing data in secure cloud-based computing instances 171 accumulate significant research costs.

Secondly, stringent data privacy laws may hinder individual countries from 172 173 participating in multicenter registry studies, and potentially impede global health by 174 slowing down responses to pandemics, such as COVID-19⁵. Finland has a long 175 tradition of nationwide healthcare registries, such as the care registry for specialized 176 healthcare, the cancer registry, and implant registries, which all have been acknowledged for their coverage and guality^{6–8}. Integrating Finnish registry holders in 177 178 international studies is possible only if data is processed in a computing environment 179 that have been audited to meet the legal requirements. Currently, only nine such 180 environments are eligible, and all are based in Finland, implying that international 181 registry studies would require transferring all data to one of these environments⁹.

The main source of error in this study stems from the prediction of new data permits 182 in 2023 in a scenario without the Secondary Use Act. However, we anticipate that 183 184 registry-based research would have gained even more popularity than before, given 185 substantial investments in healthcare information technology infrastructures facilitating the release of electronic health records to cloud-based computing 186 187 instances. Thus, many researchers experienced that the regulatory environment 188 hampered not only conventional registry-based studies but also the promising 189 progress towards automatic computer-assisted data curation and disease 190 phenotyping^{2,10}.

191 In conclusion, the results emphasize the need to balance between effective and data 192 secure research. Medical researchers should be involved in planning, interpreting and 193 assessing health data regulations. Besides their complexity, the cumulative effect of 194 European and national regulations has created a challenging environment for medical 195 researchers. Instead of improving patient privacy rights, increased administrative work 196 and excessive technology requirements to ensure security may delay research 197 projects and accumulate steeping costs. Ultimately, the regulatory burden may turn against its objectives and impede progress in patient care¹¹. 198

199 ACKNOWLEDGMENTS

200 The author wishes to thank Susanna Laurén (Turku University Hospital), Jaana Jäppinen (Helsinki University Hospital), Minna Mäkiniemi (Oulu University Hospital), 201 202 Satu Ranta (Tampere University Hospital), and Tuomas Selander (Kuopio University 203 Hospital) for providing the data for the data permit counts for their university hospital. 204 In addition, we would like to thank Antti Piirainen, Maari Parkkinen, and Johanna 205 Seppänen (Findata) for providing information on the registry holders of Findata data permits as well as for insightful comments. This study was supported by research 206 207 funding from the Helsinki University Hospital, Finnish Cancer Foundation, Research 208 Council of Finland, and the University of Helsinki.

209

210 DATA AVAILABILITY STATEMENT

211 Source data and codes are available at https://github.com/obruck/Nav-Reg-Res. 212

213 **AUTHORS' CONTRIBUTIONS**

214 Conception and design: O.B. Collection and assembly of data: O.B. Data analysis: 215 O.B. Data interpretation: All authors. Manuscript writing: O.B. Manuscript editing: All 216 authors. Final approval of manuscript: All authors.

217

218 **COMPETING INTERESTS**

219 A.B. declares being an employee of Krogerus Attorneys Ltd and (business law firm) 220 and has assisted private and public clients on matters relating to the relevant 221 legislation, outside the submitted work. O.B. declares no Competing Non-Financial 222 Interests but the following Competing Financial Interests: consultancy fees from 223 Novartis, Sanofi, GSK, Astellas, and Amgen, outside the submitted work; research 224 grants from Pfizer and Gilead Sciences, outside the submitted work; stock ownership 225 (Hematoscope Oy), outside the submitted work. E.S. declares no Competing Non-226 Financial Interests but the following Competing Financial Interests: consultancy fees 227 from Boehringer-Ingelheim, Pfizer and Orion, outside the submitted work; research 228 grant from Business Finland, outside the submitted work.

229 REFERENCES

- 230 1 Marelli L, Stevens M, Sharon T, et al. The European health data space: Too big to succeed? Health Policy 2023; 135: 104861. 231
- 232 2 Reito A, Sanmark E, Tuovinen T, et al. Enabler or suppressor? - Survey on the 233 effects of the Act on the Secondary Use of Health and Social Data on medical 234 research. Suom Lääkärilehti 2022; 77. www.laakarilehti.fi/e30589.
- 235 3 Koiste V, Siranko H. Preliminary investigation on the impact of the Act on the 236 secondary use of health and social data in research, development and innovation 237 activities and in teaching. Gesund Partners, 2022.
- 238 4 Richter G, Borzikowsky C, Lesch W, et al. Secondary research use of personal 239 medical data: attitudes from patient and population surveys in The Netherlands 240 and Germany. European Journal of Human Genetics 2021; 29: 495-502.
- 241 5 Bak M, Madai VI, Fritzsche M-C, Mayrhofer MTh, McLennan S. You Can't Have Al 242 Both Ways: Balancing Health Data Privacy and Access Fairly. Frontiers in 243 Genetics 2022; 13.
- 244 https://www.frontiersin.org/articles/10.3389/fgene.2022.929453.
- 245 6 Mäkelä KT, Furnes O, Hallan G, et al. The benefits of collaboration: the Nordic 246 Arthroplasty Register Association. EFORT Open Reviews 2019; 4: 391-400.
- 7 Sund R. Quality of the Finnish Hospital Discharge Register: A systematic review. 247 248 Scandinavian Journal of Public Health 2012; 40: 505–15.
- 249 8 Leinonen MK, Miettinen J, Heikkinen S, Pitkäniemi J, Malila N. Quality measures 250 of the population-based Finnish Cancer Registry indicate sound data guality for 251 solid malignant tumours. European Journal of Cancer 2017; 77: 31–9.
- 252 9 National Supervisory Authority for Welfare and Health. Database on secondary-253 use environments (TOINI). 2023.
- 10 Brück O, Lallukka-Brück S, Hohtari H, et al. Machine Learning of Bone Marrow 254 255 Histopathology Identifies Genetic and Clinical Determinants in MDS Patients. 256 Blood Cancer Discovery 2021; 2: 238–49.
- 257 11 Huusko J, Kinnunen U-M, Saranto K. Medical device regulation (MDR) in health 258 technology enterprises – perspectives of managers and regulatory professionals. 259 BMC Health Services Research 2023; 23: 310.
- 260

FIGURE LEGENDS 261

262 Figure 1. Registry-based research in Finland. (a) Map of Finland demonstrating cities (points) with a university hospital and their associated healthcare regions. (b) 263 264 Line plots depicting the median counts of registry data permits approved by four 265 Finnish university hospitals (black line) and data collections transferred by Findata 266 (orange line). The gray-shaded area represents the 25-75% interquartile range of 267 permit counts from university hospitals. (c) Line plots of median counts of approved 268 registry data permits by distinct Finnish university hospitals in 2015-2023. These are accompanied by fitted regression curves predicting permit counts based on trends 269 270 before the Secondary Use Act in 2015-2019 (dashed lines). (d) Data permit counts for other types than registry-based research are illustrated both individually (line plots) 271 and cumulatively (bar plots) for each university hospital. 272



А

■ Helsinki ■ Oulu ■ Kuopio ■ Tampere Data source